pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Orthopedics · news · pharmadog
← back to Orthopedics
News · Orthopedics
109
stories
Aug 31, 26
Ana Salazar Modela Tu Cuerpo Inc. Issues Nationwide Voluntary Recall of Lipofit Extreme Fat Burner 2.0 Due to Presence of Undeclared Fluoxetine and 2,4-Dinitrophenol (DNP)
fda medwatch
Aug 27, 26
Chutes & Ladders—Vivace revs up C-suite ahead of pivotal push
fiercebiotech
Aug 26, 26
Revival Animal Health, LLC Voluntarily Recalls Feline Milk Replacers Due to Inconsistent Levels of Vitamins and Trace Minerals
fda recalls
Aug 21, 26
Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug
fiercebiotech
Aug 21, 26
Opinion: Lil Nas X’s bipolar diagnosis and the paradox of treatment
stat
Aug 20, 26
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
Aug 20, 26
STAT+: FDA approves Ultragenyx gene therapy
stat
Aug 20, 26
STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
stat
Aug 20, 26
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
biospace
Aug 20, 26
Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
stat
Aug 19, 26
FDA approves Regeneron’s garetosmab for disease that turns tissue to bone
endpoints
Aug 19, 26
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy
fiercebiotech
Aug 19, 26
STAT+: Experts scrutinize Huidagene’s disclosures after patient death
stat
Aug 19, 26
STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
stat
Aug 18, 26
BioMarin acquires experimental drug for rare bone disorder in $275M deal
biopharma dive
Aug 18, 26
BioMarin does another small deal to get early-stage bone disease asset
endpoints
Aug 18, 26
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
fiercebiotech
Aug 14, 26
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
biopharma dive
Aug 10, 26
STAT+: The promise of radiopharmaceuticals smacks into safety concerns
stat
Aug 10, 26
FDA issues alert in wake of BD recall of faulty needle sets
fiercebiotech
Aug 10, 26
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
Aug 7, 26
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
Aug 6, 26
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
Aug 5, 26
Opinion: Tear down the wall between M.D. and D.O. education
stat
Aug 4, 26
Hinge Health will buy Cylinder Health for $105M to enter digestive care
endpoints
Aug 4, 26
Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey
fiercebiotech
Aug 4, 26
Smith & Nephew cuts 2026 outlook as US knee implant sales slide
fiercebiotech
Aug 4, 26
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
Aug 3, 26
STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case
stat
Jul 30, 26
Ebola outbreak nears milestone, while a vaccine remains months away
stat
← prev
page 2 of 4
next →
